CYRX earnings analysis
What we found in CYRX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Cryoport, Inc. (CYRX) reported Q1 revenue of $47.8 million, growing 16.5% year-over-year, driven by strong performance in both Life Sciences Services and Life Sciences Products segments. Despite missing EPS expectations with a loss of $0.25 against an estimate of $0.19, management issued an optimistic outlook, raising full-year revenue guidance to $192 million-$196 million.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Strong Revenue Growth
- Revenue increased by 16.5%, reaching $47.8 million compared to $41.0 million in Q1 2025.
- Segment Performance Boost
- Life Sciences Services revenue grew 17.6% to $26.9 million, while Life Sciences Products revenue increased 15.0% to $20.9 million.
- Improved Gross Margin
- Gross margin improved slightly to 45.8% from 45.4% year-over-year.
- Lower Loss from Discontinued Operations
- Loss from discontinued operations decreased significantly by 78.8% to $1.1 million.
- Increased Cash Reserves
- Cash and cash equivalents totaled $272.9 million as of March 31, 2026, up from lower levels in the prior year.
- Raising Annual Guidance
- Full-year revenue guidance has been raised to between $192 million and $196 million.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Continued Operating Losses
- The company reported a net loss of $10.5 million, indicating ongoing financial challenges.
- High SG&A Expenses
- SG&A expenses rose 26.1%, reflecting increased operational costs without corresponding revenue growth.
- Foreign Exchange Exposure
- With $29 million in foreign-denominated cash, a 20% adverse change could result in a loss of $5.8 million.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.25
- Gross margin
- 45.8%
- Segment
- Life Sciences Services: $26.9M
- Segment
- Life Sciences Products: $20.9M
What they said about what is next.
Full-year revenue guidance raised reflecting stronger performance and growth visibility.
The filing reads better than the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CYRX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever